Cargando…

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic

BACKGROUND: Poor antipsychotic (AP) adherence is a key issue in patients with schizophrenia. First-generation antipsychotic (FGA) and second-generation antipsychotic (SGA) long-acting injectable therapies (LAI) may improve adherence compared to oral antipsychotics (OAP). The objective of the study w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pilon, Dominic, Joshi, Kruti, Tandon, Neeta, Lafeuille, Marie-Hélène, Kamstra, Rhiannon L, Emond, Bruno, Lefebvre, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367457/ https://www.ncbi.nlm.nih.gov/pubmed/28356723 http://dx.doi.org/10.2147/PPA.S127623

Ejemplares similares

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2018)

Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
por: Pilon, Dominic, et al.
Publicado: (2017)

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
por: Emond, Bruno, et al.
Publicado: (2018)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia
por: Lin, Dee, et al.
Publicado: (2023)

Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
por: Dunn, Keith, et al.
Publicado: (2018)

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
por: Wysham, Carol H., et al.
Publicado: (2017)

Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
por: Bhatta, Madhav P., et al.
Publicado: (2021)

Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies
por: Correll, Christoph U., et al.
Publicado: (2023)

Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
por: El Khoury, Antoine C., et al.
Publicado: (2020)

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2013)

Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
por: Lin, Dee, et al.
Publicado: (2021)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage
por: Benson, Carmela, et al.
Publicado: (2020)

Extent of use of long-acting injectable antipsychotics in children and adolescents within Indiana Medicaid
por: Modesitt, Taylor, et al.
Publicado: (2018)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
por: Kamat, Siddhesh A, et al.
Publicado: (2015)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
por: Brasso, Claudio, et al.
Publicado: (2023)

Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus
por: Benson, Carmela, et al.
Publicado: (2020)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
por: Caballero, Joshua, et al.
Publicado: (2023)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
por: Stevens, Georgia L., et al.
Publicado: (2015)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
por: Samalin, Ludovic, et al.
Publicado: (2016)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2019)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini, Francesco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ppgbqd89s7ctljt19i6lksksp6